Entries by

Akari Therapeutics Announces Expanded Ophthalmology Program Based on Positive Emerging Data on LTB4-C5 Dual Action in Surface and Back of the Eye Diseases

26. April 2019 in /by

NEW YORK and LONDON, April 26, 2019 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announced encouraging new data in both the surface and the back of the eye. “This positive initial data […]

Ajinomoto and XL-protein forge Strategic Alliance to develop PASylated therapeutics applying the Corynex® platform

18. December 2018 in /by

SAN DIEGO, U.S.A., and FREISING, Germany, 18th December, 2018: Ajinomoto Bio-Pharma Services, a fully owned subsidiary of Ajinomoto Co. Inc. (TSE: 2802), and XL-protein GmbH, a privately owned German biopharmaceutical company, are pleased to announce a Strategic Alliance. Ajinomoto will apply its proprietary Corynex® expression system together with XL-protein’s proprietary PASylation® technology for plasma half-life […]

Horizon Pharma plc and XL-protein GmbH have entered into a collaboration agreement on a potential next-generation biologic for uncontrolled gout using PASylation® technology

7. January 2018 in /by

FREISING, January 9, 2018 /XL-protein/ — Horizon Pharma plc (NASDAQ:HZNP) yesterday announced that it has entered into a collaboration agreement with XL-protein GmbH to identify clinical-stage program candidates that could use PASylation® technology to construct a next-generation gout biologic. PASylation® technology is a biological alternative to synthetic PEGylation and is intended to extend both the […]

AdAlta and XL-protein execute commercial license agreement

13. November 2017 in /by

FREISING Germany, 13 November, 2017: XL-protein GmbH is pleased to announce the signing of a commercial agreement with AdAlta Limited (ASX:1AD), the biotechnology company advancing its lead i-body candidate towards clinical development, granting exclusive rights to deploy PASylation® technology for extended activity of AdAlta’s fibrosis therapy, AD-114, in the human body. XL-protein and the Australian […]

Jazz Pharmaceuticals and XL-protein GmbH Enter Into a License Agreement on PASylation® Technology to Develop Long-Acting Asparaginase Product Candidates

26. July 2017 in /by

Freising, July 26, 2017 /XL-protein/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it has entered into a license agreement with XL-protein GmbH (“XLp”) for the rights to develop, manufacture and commercialize products using XLp’s PASylation® Technology to extend the plasma half-life of selected asparaginase product candidates. Under the terms of the agreement, Jazz […]

AdAlta and XL-protein announce collaboration to develop a long acting version of its lead fibrosis drug candidate AD-114 using PASylation® Technology

7. November 2016 in /by

Melbourne, Australia and FREISING, Germany, 7 November 2016: AdAlta Ltd (ASX: 1AD), the biotechnology company advancing its lead i-body candidate towards clinical development, and XL-protein GmbH, a privately owned German biopharmaceutical company specialized in the design of biobetters with extended half-life, announced today that they have entered into a collaboration on the development and commercialization […]

Akari Therapeutics Plc and XL-protein GmbH Sign License Agreement to Develop a Long Acting Version of Coversin Using PASylation® Technology

14. June 2016 in /by

NEW YORK, LONDON, and FREISING, Germany, April 14, 2016 – Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, and XL-protein, a privately owned biopharmaceutical company, announced today that they have entered into a License, Development and Commercialization Agreement. This partnership is focused on developing a second generation, longer acting version of Coversin. Under […]

DNX Biopharmaceuticals and XL-protein Enter into a Shareholder Agreement to Develop and Commercialize Novel Long Acting Biopharmaceuticals.

1. February 2016 in /by

Irvine, California, and Freising, Germany, February 1, 2016 On June 30, 2015, DNX Biopharmaceuticals (“DNX”) of Irvine, California and XL-protein GmbH (“XLp”) of Freising, Germany, announced they would collaborate in the development and commercialization of novel long acting biopharma-ceutical products with financial terms undisclosed. Under this strategic collaboration, XLp contributes its half-life extension platform technology […]

XL-protein and Easton Pharmaceutical sign license agreement to develop biopharmaceuticals using PASylation® technology

17. December 2015 in /by

Freising, Germany, and Chengdu, P.R. China, December 17, 2015 — XL-protein GmbH and Easton Pharmaceutical Co., Ltd. announced today that they have entered into a License, Development and Commercialization Agreement for novel, long-acting biopharmaceutical products to address a range of unmet needs in ophthalmology and potential further indications. Under this collaboration, XL-protein will apply its proprietary […]

DNX and XL-protein Announce Collaboration to Develop Novel, Long-Acting Biopharmaceutical Products

30. June 2015 in /by

New Half-Life Extension Platform Technology Will Support the Development and Commercialization of Novel Therapeutic Proteins Addressing Unmet Needs in Immunology, Metabolism and Ophthalmology Irvine, CA and Freising, Germany, June 30, 2015 — DNX Biopharmaceuticals, Inc. (“DNX”) a company with a team of experienced industry professionals with a long and successful track record of developing and […]